Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML) Meeting Abstract
| Authors: | DiNardo, C. D.; Stein, A. S.; Stein, E. M.; Fathi, A. T.; Frankfurt, O.; Schuh, A. C.; Döhner, H.; Martinelli, G.; Raffoux, E.; Tan, P.; Zeidan, A.; de Botton, S.; Kantarjian, H. M.; Stone, R. M.; Lam, D.; Wang, X.; Gong, J.; Kapsalis, S. M.; Hickman, D.; Zhang, V.; Winkler, T.; Daigle, S.; Vyas, P. |
| Abstract Title: | Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML) |
| Meeting Title: | 7th Annual Meeting of the Society of Hematologic Oncology (SOHO 2019) |
| Keywords: | azacitidine; aml; complete remission; acute myeloid leukemia; clearance; ivosidenib; midh1 molecular |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 19 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Sep 11-14 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2019-09-01 |
| Start Page: | S217 |
| End Page: | S218 |
| Language: | English |
| ACCESSION: | WOS:000483480700131 |
| DOI: | 10.1016/j.clml.2019.07.090 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: AML-197 -- Source: Wos |
